ALKS

31.29

2.22% 0.68

Dopo l'orario di chiusura: 31.29

Alkermes Plc (ALKS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ALKS Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$30.61

Aprire:

$30.61

Volume 24 ore:

1.37M

Relative Volume:

0.81

Capitalizzazione di mercato:

$5.16B

Reddito:

$1.51B

Utile/perdita netta:

$333.35M

Rapporto P/E:

16.05

EPS:

1.95

Flusso di cassa netto:

$315.22M

1 W Prestazione:

+6.61%

1M Prestazione:

-1.54%

6M Prestazione:

+6.54%

1 anno Prestazione:

+33.72%

Intervallo 1D:

$30.25

$31.31

Intervallo di 1 settimana:

$29.30

$31.31

Portata 52W:

$22.90

$36.45

Alkermes Plc Stock (ALKS) Company Profile

Nome

Alkermes Plc

Settore

Healthcare (1166)

Industria

Drug Manufacturers - Specialty & Generic (1)

Telefono

00-353-1-772-8000

Indirizzo

CONNAUGHT HOUSE, DUBLIN 4

Dipendente

1,800

Cinguettio

@alkermes

Prossima data di guadagno

2024-10-24

Ultimi documenti SEC

ALKS's Discussions on Twitter

Confronta ALKS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALKS Alkermes Plc	31.29	4.93B	1.51B	333.35M	315.22M	1.95
HLN Haleon Plc Adr	11.41	50.54B	14.35B	1.85B	0	0.4023
ZTS Zoetis Inc	169.42	74.02B	9.29B	2.52B	2.28B	5.57
RDHL Redhill Biopharma Ltd Adr	1.80	4.22M	35.75M	11.57M	-26.25M	-3.8069
TAK Takeda Pharmaceutical Co Adr	15.08	45.82B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	17.26	20.31B	16.54B	-1.64B	749.00M	-1.45

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-05-28	Iniziato	Needham	Buy
2025-03-13	Iniziato	RBC Capital Mkts	Sector Perform
2025-03-04	Aggiornamento	UBS	Sell → Neutral
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-11-05	Aggiornamento	Stifel	Hold → Buy
2024-06-17	Iniziato	TD Cowen	Buy
2024-03-19	Iniziato	Robert W. Baird	Outperform
2024-02-20	Downgrade	UBS	Neutral → Sell
2023-11-20	Ripresa	JP Morgan	Neutral
2023-10-24	Aggiornamento	Evercore ISI	In-line → Outperform
2023-10-17	Iniziato	UBS	Neutral
2022-11-03	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-14	Aggiornamento	BofA Securities	Underperform → Neutral
2022-08-16	Iniziato	Piper Sandler	Neutral
2022-04-22	Ripresa	Goldman	Buy
2022-04-20	Iniziato	Goldman	Buy
2022-01-27	Aggiornamento	Cantor Fitzgerald	Hold → Overweight
2021-12-01	Iniziato	Citigroup	Neutral
2021-10-07	Aggiornamento	Jefferies	Hold → Buy
2021-09-02	Downgrade	BofA Securities	Neutral → Underperform
2020-10-15	Aggiornamento	Mizuho	Neutral → Buy
2020-07-30	Downgrade	Goldman	Neutral → Sell
2020-02-14	Downgrade	BofA/Merrill	Buy → Neutral
2020-02-14	Reiterato	H.C. Wainwright	Neutral
2020-02-14	Downgrade	JP Morgan	Overweight → Neutral
2020-02-06	Iniziato	Mizuho	Neutral
2020-01-31	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2019-09-05	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	Aggiornamento	Goldman	Sell → Neutral
2019-05-31	Iniziato	H.C. Wainwright	Neutral
2019-05-01	Downgrade	Citigroup	Buy → Neutral
2018-12-19	Downgrade	Goldman	Neutral → Sell
2018-12-14	Iniziato	Wolfe Research	Underperform
2018-12-13	Downgrade	Credit Suisse	Outperform → Underperform
2018-11-05	Iniziato	Piper Jaffray	Neutral
2018-08-07	Iniziato	Stifel	Hold
2018-06-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	Iniziato	B. Riley FBR, Inc.	Buy
2018-05-16	Aggiornamento	Citigroup	Neutral → Buy
2018-05-11	Iniziato	BofA/Merrill	Buy

Mostra tutto

Alkermes Plc Borsa (ALKS) Ultime notizie

04:23 AM

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | ALKS Stock News - GuruFocus

04:23 AM

04:01 AM

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - marketscreener.com

04:01 AM

11:03 AM

Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com

11:03 AM

07:00 AM

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences - PR Newswire

07:00 AM

May 31, 2025

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation? - simplywall.st

May 31, 2025

Where are the Opportunities in (ALKS) - news.stocktradersdaily.com

May 31, 2025

May 29, 2025

Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 20 - GuruFocus

May 29, 2025

Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 2025 | ALKS Stock News - GuruFocus

May 29, 2025

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 - PR Newswire

May 29, 2025

Global Healthcare & Medical Tourism News - Medical Tourism Magazine

May 29, 2025

May 28, 2025

Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga

May 28, 2025

This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

May 28, 2025

Needham Initiates Alkermes Public at Buy With $45 Price Target - marketscreener.com

May 28, 2025

Needham's Positive Outlook on Alkermes (ALKS) with Promising Sal - GuruFocus

May 28, 2025

Needham Initiates Coverage on Alkermes (ALKS) with Buy Rating | ALKS Stock News - GuruFocus

May 28, 2025

Needham's Positive Outlook on Alkermes (ALKS) with Promising Sales Projections | ALKS Stock News - GuruFocus

May 28, 2025

May 23, 2025

Stifel maintains Alkermes stock Buy rating, $42 target By Investing.com - Investing.com Nigeria

May 15, 2025

May 13, 2025

Drug Addiction Treatment Market Projected To Witness Massive - openPR.com

May 13, 2025

May 12, 2025

Drug Abuse Treatment Market Grows Amid Rising Substance Abuse - openPR.com

May 12, 2025

Cantor Fitzgerald maintains $43 target on Alkermes stock By Investing.com - Investing.com Nigeria

May 12, 2025

Controlled Release Drug Delivery Market is in trends - openPR.com

May 12, 2025

Alkermes plc Earnings Call Highlights Growth and R&D Progress - MSN

May 12, 2025

May 10, 2025

When the Price of (ALKS) Talks, People Listen - news.stocktradersdaily.com

May 10, 2025

May 03, 2025